Current status of immunisation for herpes zoster
Herpes zoster (HZ) is increasingly common in the aging and is experienced by approximately one in three people in their lifetime. It is also relatively common in immune-compromised people. Acute HZ causes severe pain, reduced quality of life and severe complications, including prolonged pain, or pos...
Saved in:
Main Authors: | Anthony Lawrence Cunningham, Kerrie Jane Sandgren, Janette Taylor |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2025-12-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2445384 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modelled Public Health Impact of Introducing Adjuvanted Recombinant Zoster Vaccine into the UK National Immunisation Programme
by: Manjit Hunjan, et al.
Published: (2024-11-01) -
A cross-sectional study exploring the predictors of herpes zoster vaccination for people aged over 50 years old in Chaoyang district, Beijing
by: Jiao Zhang, et al.
Published: (2025-01-01) -
Low vitamin D3 levels may be associated with herpes zoster
reactivation
by: Göktürk Dere, et al.
Published: (2024-11-01) -
Surveillance on the coverage of herpes zoster vaccine and post-marketing adverse events in Jiangsu province, China
by: Xiang Sun, et al.
Published: (2025-12-01) -
Comment on “Parabolic Changes in Pain Scores Among Partial Herpes Zoster Patients: A Retrospective Study” [Letter]
by: Tan Y, et al.
Published: (2025-01-01)